SOPHiA GENETICS Posts Q2 2026 Results
AI مارکیٹ کا خلاصہ
SOPHiA GENETICS reported Q2'26 revenue of $23.3m (+27% y/y) with stable net loss and a 27% narrowing in adjusted EBITDA loss, while raising FY'26 revenue guidance to $94–96m. U.S. analytics volumes rose 60% y/y, reinforcing demand momentum in clinical genomics and precision diagnostics. The update is supportive for broader precision-medicine themes, though the direct market-wide impact is limited.
اثر کی سطح
● لو
متاثرہ اثاثے
NCCOGOLD2USD/USDT+0.71%
AI تجزیاتی سمجھ · NCCOGOLD2USD/USDTAI تجزیاتی سمجھ
▲ Bullish
ابھی ٹریڈ کریں
⚠️ AI سے تیار کردہ تجزیاتی سمجھ خبروں کے مواد پر مبنی ہے اور صرف معلوماتی مقاصد کے لیے فراہم کی گئی ہے۔ یہ سرمایہ کاری کا مشورہ نہیں ہے اور نہ ہی BingX کے خیالات کی نمائندگی کرتی ہے۔ سرمایہ کاری میں رسک شامل ہے۔ براہ کرم ذمہ داری سے ٹریڈ کریں۔
SOPHiA GENETICS reported second-quarter 2026 results with revenue of $23.3 million, up 27% year over year. Reported gross margin was 64.6%. Net loss came in at $22.4 million, in line with the prior-year period. Adjusted EBITDA loss narrowed 27% to $8.8 million.
The company raised its full-year 2026 revenue guidance to $94.0 million–$96.0 million. U.S. analytics volumes increased 60% from a year earlier.
SOPHiA GENETICS provides a genomics data analytics platform. Management said the growth reflects expanding demand for clinical precision diagnostics, which is seen as a supportive read-through for precision-medicine themes and related indices such as ONCOLOGY US (ONUS).
